BVS News and Press, Bioventus Inc. From 11/09/22

Shares of Bioventus (NASDAQ: BVS) fell 14% on Wednesday. The medical device company's stock closed on Tuesday at $3 a share, then opened on Wednesday at $2.90. The stock fell to as low as $2.25 before bouncing back a bit to $2.58 at the close. The stock is down more than 82% this ye...

SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP ( www.JohnsonFistel.com ) is investigating whether Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) , any of its executive officers, or others violated securities laws by misr...

Bioventus press release ( NASDAQ: BVS ): Q3 Non-GAAP EPS of $0.08 misses by $0.04 . Revenue of $137.1M (+25.9% Y/Y) misses by $4.49M . For the twelve months ending December 31, 2022, the Company now expects: Net sales of $527 million to $532 mill...

DURHAM, N.C., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended October 1, 2022. Q3 Financial Summary & Rec...

DURHAM, N.C., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2022 bef...

DURHAM, N.C., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, will present its spine procedural solutions portfolio at the North American Spine Society (NASS) me...

Summary Avanos Medical's recent acquisition of the TriVisc portfolio creates an interesting debate for those following the hyaluronic acid market. We are holders of a competing name and so it's interesting to compare both offerings. I also demonstrate there's been a disconnect...

Summary Bioventus came in with another set of strong numbers in Q2. We reiterate the buy thesis on BVS and note there are numerous idiosyncratic risk premia on offer. The company has sorted its transaction of CartiHeal. Rate buy on $9.35 price target aiming for December 20...

DURHAM, N.C., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice-president and chief financial officer, will participate in a fireside chat at the Morgan Stanley Global Healt...

Image source: The Motley Fool. Bioventus Inc. (NASDAQ: BVS) Q2 2022 Earnings Call Aug 11, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Bioventus Inc. (BVS) Q2 2022 Earnings Call Transcript